AmerisourceBergen (NYSE:ABC) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided EPS guidance of $6.65-6.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.48. AmerisourceBergen also updated its FY19 guidance to $6.65-6.95 EPS.
NYSE:ABC traded up $2.61 during trading hours on Thursday, hitting $89.15. The stock had a trading volume of 93,256 shares, compared to its average volume of 1,525,283. The company has a debt-to-equity ratio of 1.36, a current ratio of 0.93 and a quick ratio of 0.51. AmerisourceBergen has a one year low of $73.35 and a one year high of $106.27. The company has a market cap of $18.17 billion, a price-to-earnings ratio of 13.75, a PEG ratio of 1.23 and a beta of 0.97.
AmerisourceBergen (NYSE:ABC) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.44 by $0.01. AmerisourceBergen had a net margin of 0.99% and a return on equity of 45.54%. The company had revenue of $43.30 billion during the quarter, compared to the consensus estimate of $43.27 billion. During the same period in the previous year, the firm posted $1.33 EPS. The firm’s revenue was up 10.7% compared to the same quarter last year. Equities research analysts expect that AmerisourceBergen will post 6.93 EPS for the current fiscal year.
A number of analysts have recently issued reports on the stock. Royal Bank of Canada set a $90.00 price objective on shares of AmerisourceBergen and gave the stock a hold rating in a report on Wednesday. Zacks Investment Research downgraded shares of AmerisourceBergen from a hold rating to a sell rating in a report on Wednesday, October 3rd. Mizuho reaffirmed a neutral rating on shares of AmerisourceBergen in a report on Wednesday, September 19th. ValuEngine raised shares of AmerisourceBergen from a sell rating to a hold rating in a report on Wednesday, September 19th. Finally, Robert W. Baird reaffirmed a hold rating and set a $89.00 price objective on shares of AmerisourceBergen in a report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of Hold and an average price target of $101.07.
In other AmerisourceBergen news, EVP John G. Chou sold 6,974 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $83.94, for a total value of $585,397.56. Following the completion of the sale, the executive vice president now directly owns 56,126 shares of the company’s stock, valued at $4,711,216.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven H. Collis sold 21,350 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $88.33, for a total transaction of $1,885,845.50. Following the completion of the sale, the chief executive officer now directly owns 287,925 shares of the company’s stock, valued at $25,432,415.25. The disclosure for this sale can be found here. Insiders sold 92,928 shares of company stock valued at $8,332,406 over the last three months. 27.30% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “AmerisourceBergen (ABC) Issues FY 2019 Earnings Guidance” was reported by WKRB News and is owned by of WKRB News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.wkrb13.com/2018/11/08/amerisourcebergen-abc-issues-fy-2019-earnings-guidance.html.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Recommended Story: Technical Analysis
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.